Darzalex is still the “star of the show” for Genmab

Genmab’s Darzalex royalties now cover the company’s operating costs and in addition to that, the cancer drug continues its expansion to new markets. And according to CEO, Jan van de Winkel, Genmab could potentially raise its guidance this year.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

Lægemiddelstyrelsen er skuffet, men glad for bronzen

Lægemiddelstyrelsens direktør Thomas Senderovitz er skuffet over, at København ikke skal huse EMA, men også stolt over at have snuppet "bronzemedaljerne". Han påpeger dog også, at der ligger masser af arbejde forude i forbindelse med flytningen af lægemiddelagenturet.

Latest Top picks in English

Related articles